Company intelligence / Profile preview

Panacea Global Inc

United States

Ownership: Private
Development stage: Other

Overview

Panacea Global has developed a blood test measuring HAAH enzyme levels for early detection, diagnosis, and monitoring of cancer recurrence. The test is recommended for individuals over 50 with a history of smoking and helps differentiate prostate cancer from benign conditions by providing additional information when PSA values are abnormally elevated.[4]

Therapeutic areas: Oncology
Modalities: Blood test (diagnostic assay)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Panacea Global Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panacea Global Inc.

Explore the full profile